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Abstract
Identification of regulatable mechanisms by which transcription factor NF-E2 p45-related factor 2
(Nrf2) is repressed will allow strategies to be designed that counter drug resistance associated with
its up-regulation in tumours that harbour somatic mutations in Kelch-like ECH-associated
protein-1 (Keap1), a gene that encodes a joint adaptor and substrate receptor for the Cul3-Rbx1/
Roc1 ubiquitin ligase. We now show that mouse Nrf2 contains two binding sites for β-transducin
repeat-containing protein (β-TrCP), which acts as a substrate receptor for the Skp1-Cul1-Rbx1/
Roc1 ubiquitin ligase complex. Deletion of either binding site in Nrf2 decreased β-TrCP-mediated
ubiquitylation of the transcription factor. The ability of one of the two β-TrCP-binding sites to
serve as a degron could be both increased and decreased by manipulation of glycogen synthase
kinase-3 (GSK-3) activity. Biotinylated-peptide pull-down assays identified DSGIS338 and
DSAPGS378 as the two β-TrCP-binding motifs in Nrf2. Significantly, our pull-down assays
indicated that β-TrCP binds a phosphorylated version of DSGIS more tightly than its non-
phosphorylated counterpart, whereas this was not the case for DSAPGS. These data suggest that
DSGIS, but not DSAPGS, contains a functional GSK-3 phosphorylation site. Activation of GSK-3
in Keap1-null mouse embryonic fibroblasts (MEFs), or in human lung A549 cells that contain
mutant Keap1, by inhibition of the phosphoinositide 3-kinase (PI3K) – protein kinase B (PKB)/
Akt pathway markedly reduced endogenous Nrf2 protein and decreased to 10-50% of normal the
levels of mRNA for prototypic Nrf2-regulated enzymes, including the glutamate-cysteine ligase
catalytic and modifier subunits, glutathione S-transferases Alpha-1 and Mu-1, heme oxygenase-1
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and NAD(P)H:quinone oxidoreductase-1. Pre-treatment of Keap1−/− MEFs or A549 cells with the
LY294002 PI3K inhibitor or the MK-2206 PKB/Akt inhibitor increased their sensitivity to
acrolein, chlorambucil and cisplatin between 1.9-fold and 3.1-fold, and this was substantially
attenuated by simultaneous pre-treatment with the GSK-3 inhibitor CT99021.
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Introduction
NF-E2 p45-related factor 2 (Nrf2)1 is a cap‘n’collar (CNC) basic-region leucine zipper
(bZIP) transcription factor that serves as a master regulator of redox homeostasis (1). It is
activated by thiol-reactive agents, and plays a fundamental role in cellular adaptation to
oxidative stress because of its ability to transactivate genes that contain an antioxidant
response element (ARE) in their promoter regions (2,3).
Nrf2 is principally controlled through protein ubiquitylation, which targets it for
proteasomal degradation (4-6). The N-terminal Nrf2-ECH homology (Neh)2 domain of Nrf2
contains an ETGE motif to which Kelch-like ECH-associated protein 1 (Keap1) binds with
high affinity, and a DLG motif to which Keap1 binds with low affinity (7,8); Keap1 is a
dimeric protein that serves jointly as an ubiquitin ligase adaptor and substrate receptor (9).
Under normal redox homeostatic conditions, the two subunits of Keap1 bind simultaneously
the ETGE and DLG motifs in Nrf2 and allow Cul3-Rbx1/Roc1, i.e. the cullin-ring-ligase
CRLKeap1, to ubiquitylate the transcription factor (10,11). However, upon treatment of cells
with inducing agents (such as sulforaphane or tert- butylhydroquinone) the activity of Keap1
is inhibited, CRLKeap1 no longer ubiquitylates Nrf2, the CNC-bZIP protein accumulates in
the nucleus, and ARE-driven genes become transcriptionally activated (12,13).
Often, Nrf2 is up-regulated in tumours of the head and neck, liver, lung, ovary and stomach
through loss of its repression by Keap1. This can arise as a consequence of somatic
mutations or epigenetic changes that either diminish the activity of Keap1 or reduce its
expression (14-20). Alternatively, Nrf2 may evade repression by Keap1 as a consequence of
somatic mutations in the ETGE and DLG motifs of the CNC-bZIP factor, or by
overexpression of the Nrf2 gene (21-23). As constitutive activation of Nrf2 in tumours is
associated with increased resistance to chemotherapeutic drugs and a higher rate of cell
proliferation, it is desirable to identify Keap1-independent mechanisms by which the CNC-
bZIP factor can be repressed. One such example is provided by the presence of two regions
within the Neh6 domain of Nrf2 (in mouse Nrf2 these are residues 329-339 and 363-379)
that support turnover of the CNC-bZIP protein even when Keap1 is inactivated (24). It has
also been found that glycogen synthase kinase-3 (GSK-3) inhibits Nrf2 by preventing
nuclear accumulation of the CNC-bZIP factor (25-27). Recently, evidence has been
provided that GSK-3-catalysed phosphorylation of the Neh6 domain in Nrf2 creates a
phosphodegron to which the substrate receptor β-transducin repeat-containing protein (β-
TrCP)2 is recruited (28); β-TrCP contains an F-box domain that interacts with the Skp1
adaptor protein, and a WD40 domain that binds substrates (29). Collectively, these findings
suggest that the phosphodegron created by GSK-3 enables ubiquitylation of Nrf2 by the
Skp1-Cul1-Rbx1/Roc1 core E3 complex, i.e. SCFβ-TrCP.
1Nrf2 is sometimes referred to as NF-E2-like 2 (nfe2l2).
2Note that two mammalian β-TrCP paralogues exist (i.e. β-TrCP1 and β-TrCP2) which possess similar properties. In this paper we
have employed the general term β-TrCP, rather than defining the isoform, unless specific experimental details are described.
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Whilst progress has been made in understanding how the N-terminal degron within the Neh6
domain of Nrf2 operates, the molecular mechanism by which the other degron in Neh6
functions is not known. It has also not not been examined whether Nrf2 can be down-
regulated by activation of its Neh6-based degrons. It is important to explore this possibility
as it might provide a strategy to counter Nrf2-mediated drug resistance.
Results
To gain a better understanding of which amino acids within Neh6 direct degradation of Nrf2
protein, a sequence alignment from different species was undertaken. Figure 1A shows that
the Neh6 domain contains two regions that are highly conserved across vertebrates. One of
these, called SDS1, is located in mouse Nrf2 between amino acids 329-342 in the N-
terminal portion of Neh6 and contains a putative DSGIS338 non-canonical β-TrCP-binding
site (ref. 28)3. The second region, designated SDS2, is located in mouse Nrf2 between
amino acids 363-379 in the C-terminal portion of Neh6 and contains a possible β-TrCP-
binding site formed by DSEME370 and a more likely β-TrCP-binding site involving
DSAPGS378. Both SDS1 and SDS2 contain putative GSK-3 phosphorylation sites. The
SDS2 region is situated within a possible PEST sequence that lies between amino acids
347-380 (6). As shown in Figure 1B, the SDS1 region is conserved in acidic domain-2 of
NF-E2 p45-related factor 1 (Nrf1). The putative DSGIS β-TrCP binding site within SDS1 of
Nrf2 is represented by DSGLS in Nrf1, and the latter has recently been reported to recruit β-
TrCP (30). Although the SDS2 region is represented in the Neh6-like domain of Nrf1, the
potential DSEME and DSAPGS β-TrCP binding sites are poorly conserved (Figure 1C).
The stability and activity of Nrf2 is controlled through two separate sequences within its
Neh6 domain
The degron activity of different regions within Neh6 was studied by examining the stability
of various Nrf2 deletion mutants, all of which lacked the N-terminal Neh2 domain. Deletion
of the SDS1 region or the PEST sequence increased the stability of Nrf2ΔNeh2-V5 in
Keap1−/− mouse embryonic fibroblast (MEF) cells (Figure 2A), with the half-life estimated
to increase from 70 min for Nrf2ΔNeh2-V5 to about 212 and 185 min for Nrf2ΔNeh2,SDS1-V5
and Nrf2ΔNeh2,PEST-V5, respectively (Figure 2B). Deletion of both SDS1 and PEST further
increased the half-life of Nrf2ΔNeh2-V5 to 263 min. Moreover, forced co-expression of β-
TrCP1 with Nrf2ΔNeh2-V5 in Keap1-null MEFs greatly diminished the amount of the
mutant CNC-bZIP protein detected by immunoblotting (Figure 2A). By contrast, forced
expression of the adaptor protein had only a small effect on the abundance of
Nrf2ΔNeh2,SDS1-V5 in Keap1−/− MEFs, whereas it decreased modestly the level of
Nrf2ΔNeh2,PEST-V5. Deletion of both SDS1 and PEST, or deletion of the entire Neh6
domain within Nrf2ΔNeh2-V5, rendered the compound mutant CNC-bZIP protein insensitive
to destabilization by forced expression of β-TrCP.
In order to assess the functional significance of the reduction in steady-state Nrf2 protein
levels affected by forced expression of β-TrCP, the ability of Nrf2ΔNeh2-V5-based mutants
to transactivate an ARE-luciferase reporter gene, based on the promoter of mouse
NAD(P)H:quinone oxidoreductase-1 (Nqo1) (2), was examined in COS1 cells (Figure 2C).
An expression vector for Nrf2ΔNeh2-V5 produced a 3.5-fold increase in relative luciferase
activity. However, this increase was almost completely abolished on co-transfection with an
expression vector for β-TrCP, and was further decreased upon expression of constitutively
active GSK-3βΔ9. Following transfection with an expression vector for Nrf2 lacking both
3Throughout this paper expression constructs encoding mouse Nrf2 have been studied, and thus the numbering of amino acids is
based on the murine CNC-bZIP transcription factor.
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Neh2 and the SDS1 region (Nrf2ΔNeh2,SDS1), an increase in luciferase activity of 4.8-fold
was observed (compared with a 3.5-fold increase stimulated by Nrf2ΔNeh2), and this was
reduced to a ~3.6-fold increase in activity upon co-expression of β-TrCP. By contrast with
Nrf2 and Nrf2ΔNeh2, the activity of Nrf2ΔNeh2,SDS1 was not inhibited by GSK-3βΔ9 (Figure
2C). Transfection with an expression vector for Nrf2ΔNeh2 lacking the PEST sequence
produced an approximate 4-fold increase in luciferase activity that was reduced to a 2.5-fold
increase in reporter activity on co-expression of β-TrCP. However, unlike Nrf2ΔNeh2,SDS1,
the reduction in the luciferase activity produced by the Nrf2ΔNeh2,PEST mutant that occurred
on co-expression of β-TrCP was further decreased by GSK-3βΔ9 (Figure 2C). Transfection
of COS1 cells with an expression vector for Nrf2 lacking Neh2 and both SDS1 and PEST
sequences produced an approx. 5.5-fold increase in luciferase activity, and this increase was
not inhibited by ectopic expression of β-TrCP and GSK-3βΔ9.
Nrf2 contains two separate β-TrCP binding regions within its Neh6 domain
The above data suggest that the PEST sequence in the Neh6 domain contains a degron that
interacts with β-TrCP. In order to locate the degron more accurately, Nrf2 expression
constructs were made in which the PEST sequence was deleted in two halves, N-
PEST347-362 and SDS2 (i.e. C-PEST363-379). Using COS1 cells, the contributions made by
SDS1 and SDS2 to the association of Nrf2 with β-TrCP1 were compared by co-
immunoprecipitation (co-IP) of ectopic V5-tagged Nrf2 deletion mutants with FLAG-tagged
β-TrCP1. Western blotting of material precipitated with anti-FLAG antibody revealed that
the association between Nrf2 and β-TrCP was markedly reduced on deletion of either the
SDS1 or SDS2 regions (Figure 3A), whereas deletion of N-PEST347-362 did not influence
the association between Nrf2 and β-TrCP1 (data not shown).
The co-IP assay was also performed to investigate the significance of putative β-TrCP
recognition sites within the SDS1 and SDS2 regions in the Neh6 domain of Nrf2. Deletion
of the SDSGIS338 peptide from within SDS1 of the murine CNC-bZIP factor resulted in a
dramatic decrease in the amount of mutant Nrf2 precipitated with β-TrCP (Figure 3B). By
contrast, deletion of the SDSEME370 peptide within SDS2 did not influence the association
of Nrf2 with β-TrCP, whereas deletion of the DSAPGS378 peptide within SDS2 caused a
significant reduction in the amount of the CNC-bZIP protein pulled-down with β-TrCP.
These results support the hypothesis that both SDSGIS338 and DSAPGS378 motifs in the
Neh6 domain are recognised by β-TrCP whereas SDSEME370 is not bound by β-TrCP.
A separate co-IP assay was used to test whether the Neh6 domain is sufficient to allow Nrf2
to interact with β-TrCP. We created an EYFP-Neh6 fusion protein, along with mutants that
lacked the SDSGIS338, SDSEME370 and DSAPGS378 peptide sequences, and examined
whether they could be precipitated with β-TrCP. The assay revealed that β-TrCP pulled-
down EYFP-Neh6. Deletion of either SDSGIS or DSAPGS significantly reduced the
amount of EYFP-Neh6 that could co-IP with β-TrCP but deletion of SDSEME did not
diminish the amount of EYFP-Neh6 precipitated with β-TrCP (Figure 3C).
GSK-3 activity influences the association between Neh6 and β-TrCP
We created a mammalian two-hybrid assay to further examine the interactions between the
Neh6 domain of mouse Nrf2 and the WD-40 domain of β-TrCP1 that comprised
Gal4(DBD)-Neh6 and Gal4(AD)-WD40 fusion proteins along with a Gal4-driven luciferase
reporter gene. As shown in Figure 4A, co-expression of the Gal4(DBD)-Neh6 and
Gal4(AD)-WD40 fusion proteins in COS1 cells along with the Gal4 PTKUAS-Luc reporter
plasmid, produced an approximate 3.2-fold increase in luciferase activity, when compared
with the activity obtained upon expression of either Gal4(DBD)-Neh6 or Gal4(AD)-WD40
alone. Most significantly, deletion of the SDSGIS and DSAPGS peptides from the murine
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Neh6 domain decreased induction of luciferase activity from 3.2-fold to just 1.5-fold and
2.1-fold, respectively.
When constitutively active GSK-3βΔ9 was included in the mammalian two-hybrid assay, we
found that Gal4-driven luciferase activity in cells expressing Gal4(DBD)-Neh6 increased
from 3.2-fold to 4.0-fold (Figure 4B). Ectopic GSK-3βΔ9 did not however increase Gal4-
driven luciferase activity in cells expressing Gal4(DBD)-Neh6 that lacked SDSGIS. By
contrast, GSK-3βΔ9 increased Gal4-driven luciferase activity from about 2.3-fold to 3.1-fold
in cells expressing Gal4(DBD)-Neh6that lacked DSAPGS. When the kinase-dead
GSK-3βY216F mutant was included in the mammalian two-hybrid assay, Gal4-driven
luciferase activity in cells expressing Gal4(DBD)-Neh6 lacking SDSGIS was again
unaltered by forced expression of the GSK-3 protein (Figure 4C).
GSK-3 alters the abundance of a Neh6-containing fusion protein through a single peptide
sequence
To test whether GSK-3 activity influences the degron activities of the SDSGIS or DSAPGS
sequences, we created an expression vector for a Neh6(LacZ)-V5 fusion protein and deletion
mutants that lack the two motifs. Transfection of COS1 cells with an expression vector for
Neh6(LacZ)-V5 gave a level of β-gal activity that was clearly discernable from background.
By contrast with ‘wild-type’ Neh6(LacZ)-V5, a fusion protein lacking SDSGIS gave a 6.2-
fold increase in β-gal activity and one lacking DSAPGS gave a 2.5-fold increase in activity
(Figure 5A).
Treatment of COS1 cells that expressed ectopic ‘wild-type’ Neh6(LacZ)-V5 with the GSK-3
inhibitor CT99021 increased β-gal activity ~2.0-fold when compared with COS1 cells
expressing the ‘wild-type’ fusion protein that had been treated with vehicle alone (Figure
5B). Treatment of COS1 cells that expressed ectopic Neh6ΔSDSGIS(LacZ)-V5 with the
GSK-3 inhibitor did not increase β-gal activity over that observed in vehicle-treated cells.
Treatment of cells that expressed ectopic Neh6ΔDSAPGS(LacZ)-V5 with the CT99021
GSK-3 inhibitor increased β-gal activity an additional 1.8-fold when compared with cells
expressing the same fusion protein that had been treated with vehicle alone.
GSK-3 activity increases ubiquitylation of Nrf2 through a single peptide in the Neh6
domain
An in-vivo ubiquitylation assay was performed to assess the biological significance of the
two β-TrCP binding motifs in the Neh6 domain. Expression constructs for Nrf2Δ17-32-V5
with or without the SDSGIS338 or DSAPGS378 peptides were co-transfected into COS1 cells
with FLAG-tagged β-TrCP and pHisUb. Deletion of either the SDSGIS338 or DSAPGS378
peptide within Nrf2 led to a significant decrease in its ubiquitylation (Figure 6A). Moreover,
combined deletion of both peptide sequences resulted in complete inhibition of
ubiquitylation.
Forced expression of constitutively active GSK-3βΔ9 increased ubiquitylation of
Nrf2Δ17-32-V5 that contained the SDSGIS338 motif but not those mutants that lacked it
(Figure 6B). Moreover, the GSK-3 inhibitor CT99021 only inhibited ubiquitylation of
Nrf2Δ17-32-V5 forms that contained the SDSGIS338 sequence (Figure 6C). Thus,
ubiquitylation of Nrf2 through the SDSGIS sequence is influenced by GSK-3 whereas
ubiquitylation of Nrf2 through the DSAPGS378 sequence occurs independently of the
kinase.
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Phosphorylation of the DSGIS338 motif in the Neh6 domain of Nrf2 increases binding by β-
TrCP
To define the sequences in the Neh6 domain of Nrf2 to which β-TrCP binds, a biotinylated-
peptide pull-down assay was carried out. A series of scanning mutants were synthesised
across the (SGSG)-328MEFNDSDSGISLNTSPSR345 and
(SGSG)-367SEMEELDSAPGSVKQNGP384 peptides in which NDSDSGISLN340 and
ELDSAPGSVK380 sequences (with the residues previously deleted in Neh6 shown in bold
italics), respectively, were each replaced individually with Ala; the Ala-375 residue was left
unchanged. As shown in Figures 7A and B, the pull-down assay indicated that the sequences
DSGIS338 and DSAPGS378 represent the core destruction motifs to which β-TrCP binds.
The peptide pull-down assay was next employed to test whether binding of β-TrCP to
peptides containing DSGIS or DSAPGS was influenced by phosphorylation. An increase in
binding between the immobilized DSGIS-containing peptide and β-TrCP was observed on
phosphorylation of Ser-335 and Ser-338, giving DpSGIpS (Figure 7C). By contrast, no
increase in binding between the immobilized DSAPGS-containing peptide and β-TrCP was
observed on phosphorylation of Ser-374 and Ser-378, giving DpSAPGpS.
The biotinylated-peptide pull-down assay was also used to test whether the increase in
binding of β-TrCP to phosphorylated DSGIS was due to either Ser-335 and/or Ser-338. The
data in Figure 7D indicate that β-TrCP binds DSGIS-containing peptides with a single
phosphorylation at either Ser-335 or Ser-338 better than the unphosphorylated peptide.
Moreover, relative to the di-phosphorylated peptide at Ser-335 and Ser-338 (i.e.
DpSGIpS338), β-TrCP did not show a further increase in binding towards tri-phosphorylated
peptides with additional phosphoserines at positions 333 or 342.
Activation of GSK-3 decreases Nrf2 protein levels and increases sensitivity to anti-cancer
drugs
GSK-3α and GSK-3β are negatively regulated by phosphorylation of their Ser-21 and Ser-9
residues, respectively (31,32). We hypothesised that augmenting the activity of GSK-3α/β
by blocking phosphorylation of Ser-21/Ser-9 might down-regulate Nrf2, as a consequence of
maximizing phosphorylation of the DSGIS motif and thus its turnover via SCFβ-TrCP. To
test this idea, we used inhibitors to prevent protein kinase B (PKB)/Akt from inactivating
GSK3α/β; LY294002 was used to inhibit the upstream phosphoinositide 3-kinase (PI3K),
and MK-2206 was used to inhibit the proximal PKB/Akt. Treatment of COS1 cells that had
been transfected with an expression plasmid encoding Neh6(LacZ)-V5 for 8 h with 10 μM
LY294002 or 5 μM MK-2206 decreased the amount of the V5-tagged ‘wild-type’ Neh6-
LacZ fusion protein by 80% (Figure 8A). However, the amount of the V5 epitope detected
from the Neh6ΔSDSGIS(LacZ)-V5 mutant was not affected by LY294002 or MK-2206. As
anticipated, the levels of both Neh6ΔSDSEME(LacZ)-V5 and Neh6ΔDSAPGS(LacZ)-V5 were
diminished by LY294002 or MK-2206. These observations suggest that the PI3K-PKB/Akt
pathway regulates Nrf2 activity via the DSGIS motif.
To test whether activation of GSK-3 in Keap1−/− MEFs results in a loss of endogenous Nrf2
protein, we treated the fibroblasts with LY294002 or MK-2206. Treatment of the knockout
MEFs with increasing concentrations of either LY294002 or MK-2206 for 8 h resulted in a
substantial decrease in the amount of Nrf2 protein at the higher doses of inhibitor (Figure
8B). The reduction in Nrf2 protein levels coincided with a decrease in inhibitory
phosphorylation of GSK-3β at Ser-9, and loss of activating phosphorylation of PKB/Akt at
Ser-473. These data suggest failure to inhibit GSK-3 by its N-terminal phosphorylation is
associated with increased turn-over of the CNC-bZIP transcription factor.
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The biochemical consequence of Nrf2 down-regulation in Keap1−/− MEFs by LY294002 or
MK-2206 was examined by measuring expression of endogenous ARE-driven genes. At the
doses used, we found treatment of fibroblasts with LY294002 for 2 h followed by transfer to
fresh medium containing 0.1% FBS for a further 6 h produced marginally greater decreases
in mRNA levels for Nqo1, heme oxygenase-1 (Hmox1), glutamate-cysteine ligase catalytic
(Gclc) and modifier (Gclm) subunits, and glutathione S-transferase Alpha-1 (Gsta1) and
Mu-1 (Gstm1) subunits than did MK-2206 (Figure 8C). Specifically, the mRNA species for
Nqo1, Hmox1, Gclc, Gclm, Gsta1 and Gstm1 were reduced by 10 μM LY294002 to 18%,
28%, 21%, 24%, 16% and 36% of control levels, respectively, whereas the same mRNAs
were decreased by 5 μM MK-2206 to 42%, 33%, 32%, 33%, 42% and 61% of control,
respectively.
To test whether the decreases in Nrf2 protein and its target genes caused by LY294002 and
MK-2206 might increase sensitivity to anticancer drugs, Keap1−/− MEFs were pre-treated
with 10 μM LY294002 or 5 μM MK-2206 for 8 h before the fibroblasts were exposed to
increasing doses of acrolein, cisplatin or chlorambucil. Figure 9A shows that the EC50 dose
of acrolein, cisplatin and chlorambucil was 68, 575 and 70 μmol/l in Keap1−/− MEFs that
had not been pre-treated with either LY294002 or MK-2206. However, the EC50 values for
acrolein, cisplatin and chlorambucil were reduced to 22, 200 and 25 μmol/l, respectively,
when they were pre-treated with the PI3K inhibitor. Figure 9B shows that the EC50 dose of
acrolein, cisplatin and chlorambucil was reduced to 33, 270 and 40 μmol/l when the
fibroblasts were pre-treated with the PKB/Akt inhibitor MK-2206. Thus, pre-treatment of
Keap1−/− MEFs with LY294002 or MK-2206 can increase their sensitivity towards acrolein,
cisplatin and chlorambucil between 1.8-fold and 3.1-fold. Inclusion of the GSK-3 inhibitor
CT99021 with the kinase inhibitor pre-treatment regimen abolished the increased sensitivity
to chlorambucil conferred by LY294002 or MK-2206. However, CT99021 only partially
countered the increased sensitivity towards acrolein and cisplatin conferred by LY294002 or
MK-2206. These results are consistent with the hypothesis that the increased sensitivity
caused by LY294002 or MK-2206 towards chlorambucil requires de-repression of GSK-3
activity, whereas this is only partially true for acrolein and cisplatin.
As the above experiments were performed in Keap1-null MEFs, we also examined whether
de-repression of GSK-3 might decrease the expression of Nrf2-target genes in human cells
with mutant Keap1, and render them more sensitive to anticancer drugs. To this end we
examined human pulmonary epithelial A549 cells as they have been reported to harbour
Keap1 encoding a protein with a Gly to Cys change at amino acid 333 (14) and to exhibit
hypermethylation of the Keap1 promoter (17). Figure 10A shows that treatment of A549
cells with LY294002 or MK-2206 decreased significantly the level of Nrf2 protein and this
was associated with both a decrease in activating phosphorylation of Ser-473 in PKB/Akt
and a loss of inhibitory phosphorylation of GSK-3 β at Ser-9. Following treatment of A549
cells with LY294002 or MK-2206, the amount of mRNA for NQO1, HMOX1, GCLC and
GCLM was decreased to 10%-50% of normal (Figure 10B). However, the decrease in
mRNA for aldo-keto reductase (AKR) 1B10 and AKR1C1, both of which are members of
the human ARE-gene battery (3), was not so obvious. As was the case with Keap1−/− MEFs,
treatment of A549 cells with LY294002 or MK-2206 increased the sensitivity of the human
lung cells to acrolein, cisplatin and chlorambucil (Figure 11).
Discussion
Many short-lived regulatory proteins that contribute to tumourigenesis are controlled by
ubiquitylation via SCFβ-TrCP (33). Originally, β-catenin and IκBα were identified as
substrates for SCFβ-TrCP and shown to contain similar destruction motifs, with the consensus
sequence DSGΦXS (where Φ is a hydrophobic residue, and X is any amino acid), to which
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β-TrCP binds following their phosphorylation by GSK-3 (34,35). Herein we report the
identification of two non-identical binding motifs for β-TrCP within the Neh6 domain of
Nrf2. One of these is the non-prototypic sequence DSGIS, which is conserved in vertebrate
species, and has been observed previously in the erythropoietin receptor (36) and in the Yes-
associated protein (YAP) transcription coactivator (37). The second β-TrCP-binding site in
Nrf2 is the peptide sequence DSAPGS, which has not been identified before. It does
however resemble the destruction motifs in the Cdc2 inhibitory kinase Wee1A (i.e.
DSAFQE) and in the NF-κB 2 gene product p100 (i.e. DSAYGS) (38,39). Both the DSGIS
and DSAPGS motifs in the Neh6 domain of Nrf2 are each sufficient to enable ubiquitylation
of the CNC-bZIP protein by SCFβ-TrCP.
GSK-3 activity antagonises Nrf2 (25), and this has been postulated to entail the formation of
a phosphodegron that is recognised by β-TrCP (28). The present study indicates that the
DSGIS destruction motif in Nrf2 is influenced by GSK-3 whereas the DSAPGS motif is not.
Our in vitro biotinylated peptide pull-down assay indicated that non-phosphorylated DSGIS-
and DSAPGS-containing peptides are recognised by β-TrCP suggesting that GSK-3 activity
is not essential for SCFβ-TrCP ubiquitylation of Nrf2. However, the pull-down assay also
revealed that phosphorylated DSGIS-containing peptides are bound more avidly by β-TrCP
than the non-phosphorylated peptide, whereas this was not the case for the DSAPGS-
containing peptide. These findings are consistent with the mammalian two-hybrid
experiment, which showed that the interaction between Nrf2-derived proteins containing the
DSGIS peptide and the β-TrCP substrate adaptor (or its WD-40 domain) was diminished,
but not abolished, by treatment with the GSK-3 inhibitor CT99021.
Through creating a phosphodegron in Nrf2 that is recognized by SCFβ-TrCP, it seems that
GSK-3 provides a pivotal control hub by which the CNC-bZIP factor can be both up- and
down-regulated. The activity of GSK-3α/β is positively regulated by phosphorylation of a
“T-loop” Tyr residue (Tyr-279 in GSK-3α, Tyr-216 in GSK-3β) and negatively regulated by
phosphorylation of an N-terminal Ser residue (Ser-21 in GSK-3α, Ser-9 in GSK-3β) (40).
Also, GSK-3β is inactivated by p38 MAPK-mediated phosphorylation of Ser-389 and
Thr-390, and by ERK-mediated phosphorylation of Thr-43. PKB/Akt represents an
important negative regulator of GSK-3α/β, and in this study we have used the PKB/Akt
inhibitor MK-2206 and the PI3K inhibitor LY294002 to increase GSK-3 activity, and thus
down-regulate Nrf2. It is well documented that GSK-3 can be inhibited by the actions of
ERK, p38 MAPK, PI3K and PKC (40). Interestingly, these kinases have been reported to
influence ARE-driven gene expression (41-47) but it remains unclear whether they alter
Nrf2 activity by direct or indirect mechanisms (48). Notably, Rojo et al (49) have proposed
that the phytochemical nordihydroguaiaretic acid stimulates Nrf2-mediated induction of
ARE-driven genes by activating the PI3K-PKB/Akt pathway, which in turn inhibits GSK-3
and prevents formation of the Neh6-phosphodegron recognised by SCFβ-TrCP. We now
propose that ERK, p38 MAPK and PKC may all similarly regulate Nrf2 indirectly by
inhibiting GSK-3. In addition, a ‘priming’ kinase is required to phosphorylate a substrate
before GSK-3 is able to carry out further modifications (50). In the case of Nrf2, the identity
of the ‘priming’ kinase is unknown, but this represents another point at which formation of
the DpSGIpS phosphodegron might be controlled.
A key question concerns the relationship between β-TrCP and Keap1. Whilst both
CRLKeap1and SCFβ-TrCP function independently, it is not known to what extent each
influences the expression of Nrf2-target genes under normal homeostatic conditions.
Furthermore, it is unclear to what extent SCFβ-TrCP restrains the expression of Nrf2-target
genes when inducing agents inhibit CRLKeap1. One possibility is that CRLKeap1 and
SCFβ-TrCP have tissue-specific effects with the activity of the latter being influenced by
metabolism and proliferation. Another is that Keap1 and β-TrCP regulate Nrf2 in different
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sub-cellular compartments. It is widely accepted that Keap1 is located primarily in the
cytoplasm (51). By contrast it is possible that β-TrCP regulates Nrf2 predominantly in the
nucleus. Discrepancies unfortunately exist regarding the sub-cellular localization of the β-
TrCP1 and β-TrCP2 isoforms and their splice variants (β-TrCP1α, β-TrCP1β, β-TrCP2α,
β-TrCP2β and β-TrCP2γ) (52,53). Interestingly, other components of the ubiquitylation
machinery, including Cdc34, Skp1 and Cul-1, have been identified within the nucleus (54).
Therefore it is likely that degradation of Nrf2 by SCFβ-TrCP is, at least in part, a nuclear
event.
Activation of the Neh6 phosphodegron in Nrf2 that is created by GSK-3 represents a
strategy by which overexpression of the CNC-bZIP factor might be countered in drug-
resistant tumours with somatic mutations in Keap1. However, down-regulation of Nrf2 is
likely to sensitize normal tissues to the toxic effects of anticancer agents, and therefore
therapeutic selectivity needs to be considered carefully before embarking on this approach.
We envisage that down-regulation of Nrf2 might provide therapeutic selectivity in the
treatment of tumours that endure a higher burden of reactive oxygen species (ROS) than
normal tissues. Specifically, tumours harbouring oncogenic Ras, Bcr-Abl or Myc produce
relatively high levels of ROS (55), and at least some of these are likely to be dependent on
Nrf2 for survival (23). It might be imagined that tumours harbouring oncogenes that
increase ROS production would be more susceptible than normal tissues to apoptosis
stimulated by oxidative stress, and that this potential vulnerability could be increased further
by the administration of drugs that increase ROS levels.
In conclusion, we have demonstrated that the Neh6 domain of Nrf2 contains two distinct
destruction motifs, the activity of one of which, DSGIS, is increased by GSK-3 activity (see
Figure 12 for a model). Thus, in tumours in which Nrf2 is constitutively up-regulated,
stimulation of the DSGIS degron by activation of GSK-3 represents a potentially useful
therapeutic approach to overcome drug resistance and inhibit cell proliferation.
Materials and Methods
Chemicals
The GSK-3 inhibitor CT99021 was synthesized as described elsewhere (56). Other
chemicals were commercially available.
Expression plasmids
Expression plasmids for C-terminally V5-tagged wild-type mouse Nrf2 (Nrf2-V5) and
Nrf2Δ17-32-V5 (i.e. pcDNA3.1/V5mNrf2 and pcDNA3.1/V5mNrf2Δ17-32) have been
described previously (4,24). We created the following deletions within pcDNA3.1/V5mNrf2
by site-directed mutagenesis (SDM) using primers listed in Table 1 in the Supplemental
Material: Δ3-96 (called ΔNeh2), Δ300-385 (called ΔNeh6), Δ329-342 (called ΔSDS1),
Δ333-338 (called ΔSDSGIS), Δ347-362 (called ΔN-PEST), Δ350-380 (called ΔPEST),
Δ363-379 (called ΔC-PEST or ΔSDS2), Δ365-370 (called ΔSDSEME) and Δ373-378
(called ΔDSAPGS).
An expression plasmid for a YFP-Neh6 fusion protein was created by ligating the cDNA
encoding amino acids 300-380 of mouse Nrf2 into the BamHI/XbaI site in the pEYFP-C1
plasmid (Clontech) to yield a vector for YFP fused at its C-terminus to the N-terminal end of
Neh6 called pEYFP-C1/mNeh6. This plasmid was used as a template to generate deletion
mutants within Neh6 by SDM.
An expression construct for N-terminally hexahistidine-Xpress tagged mouse β-TrCP1
protein (pcDNA4/HisMaxBmβTrCP1) was generated by PCR of the mouse β-TrCP1 coding
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region in IMAGE clone 3491843 using oligonucleotides bearing mismatches that introduced
BamHI and XhoI sites, and following restriction the product was ligated into pcDNA4/
HisMaxB (Invitrogen). In order to create an expression vector for a C-terminal FLAG-
tagged form of β-TrCP1, the DYKDDDDK epitope was engineered into the β-TrCP1 TAA
stop codon within pcDNA4/HisMaxBmβTrCP1 and the nonsense codon was reintroduced
immediately C-terminal to the epitope, giving pcDNA4/HisMaxBmβTrCP1-FLAG. An
expression construct for mouse β-TrCP1 that uses the T7 promoter was created by
subcloning the cDNA for β-TrCP1 into the BamHI/XhoI site of pcDNA3 to give pcDNA3/
HismβTrCP1.
For mammalian two-hybrid experiments, cDNA encoding amino acids 300-380 of mouse
Nrf2, and the various deletion mutants therein, were ligated into the BamHI/EcoRI site in
pcDNA3.1/Gal4D-V5 (57) to give a plasmid encoding the Gal4 DNA-binding domain fused
at its C-terminus to Neh6 (i.e. Gal4(DBD)-Neh6), which was called pcDNA3.1/Gal4(DBD)-
Neh6. The cDNA encoding amino acids 303-581 of mouse β-TrCP1, comprising the WD-40
domain, was ligated into the BamHI/HindIII site in the Gal4 activation domain plasmid
pVP16, giving the plasmid pV16/WD40 that encoded Gal4(AD)-WD40.
For LacZ reporter experiments, cDNA encoding amino acids 290-410 of mouse Nrf2, and
various deletion mutants, were ligated into the KpnI/BamHI site in pcDNA3.1/V5-His/lacZ.
A nuclear localization signal, RKKKRKV, from SV40 was engineered to be contiguous
with both the C-terminus of amino acids 290-410 from Nrf2 and the N-terminus of LacZ,
giving the plasmid pcDNA3.1/V5mNeh6-NLS-LacZ that encoded a Neh6-LacZ-V5 fusion
protein.
Expression vectors for N-terminally HA-tagged constitutively active GSK-3βΔ9 (pCGN/
GSK-3βΔ9) and N-terminally HA-tagged kinase-dead GSK-3βY216F (pCGN/GSK-3βY216F)
have been reported previously (58,59).
Cell biology
Keap1−/− MEF, COS1 and A549 cells were routinely grown in Delbecco’s modified Eagle’s
medium containing 10% FBS (28). The ability of various Nrf2-V5 mutant proteins to co-IP
with FLAG-tagged β-TrCP1 was assessed by standard methods (7). ARE-driven reporter
gene expression was determined as described previously (2). In vivo ubiquitylation was
determined by the method of Treier et al (60). MTT cytotoxicity testing was performed as
described elsewhere (61).
Mammalian two-hybrid assay
COS1 cells were co-transfectased with expression vectors for Gal4(DBD)-Neh6, or one of
its deletion mutants, and Gal4(AD)-WD40 protein along with the Gal4-driven luciferase
reporter plasmid PTKUAS-Luc and the pRL-TK Renilla Luciferase reporter vector that was
used to control for transfection efficiency (57). Approximately 48 h after transfection, the
cells were serum-depleted by transfer to media containing 0.5% FBS for 16 h before
luciferase activity was measured. Results were normalized to the Renilla luciferase
luminescence.
Peptide binding assay
The ability of β-TrCP1 to bind peptides designed around possible destruction motifs in the
Neh6 domain of Nrf2 was examined by a peptide pull-down assay (62). The peptides studied
comprised 22 amino acids, each including the tetra-peptide SGSG sequence at the N-
terminus that was coupled to Biotin, and the remainder representing amino acids 327-344,
359-376 or 367-384 from mouse Nrf2; see Tables 2 and 3 in the Supplemental Material. In
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the assay, [35S]methionine-labelled mouse β-TrCP1, produced from pcDNA3/HismβTrCP1
using a TNT Quick Coupled Transcription/Translation System (Promega), was tested for its
ability to adsorb to the above synthetic peptides that had been biotinylated and coupled to
Streptavidin-agarose beads overnight. The in vitro translated and labelled β-TrCP1 protein
was allowed to interact for 120 min at 4°C with the immobilized peptides, and after
extensive washing the relative amount of protein bound to given aliquots of the beads was
determined by measurement of the amount of [35S]methionine-labelled protein of correct
size when examined by autoradiography following SDS/PAGE.
Protein and mRNA analyses
Immunoblotting was performed by standard methods. Antibodies that cross-react with
phospho Ser-9 of GSK-3β (ab30619) were from Abcam, and those that recognise both
phospho Ser-21 of GSK-3 α and phospho Ser-9 of GSK-3β (#9331) were from Cell
Signalling. Antibodies against Nrf2, Nqo1 and Hmox1 have been described previously
(2,7,49). Other antibodies were readily available from commercial sources. Measurement of
mRNA levels in Keap1-null MEFs and A549 cells was carried out by TaqMan reverse
transcription-polymerase chain reaction (RT-PCR) as described previously (2,61,63).
Statistical analyses
The significance of results was assessed using GraphPad Prism 5 software and either One-
Way ANOVA or Two-Way ANOVA, Newman-Keuls Multiple Comparison Test. Mean ±
SD results in which the P value was >0.05 were deemed to be not significant (ns). Increases
in the mean ± SD results for which the P values were between 0.05 and 0.01, between 0.01
and 0.001, or <0.001 are indicated by single, double, or triple asterisks (*), respectively.
Similarly, the significance of decreases in mean ± SD results is indicated by single, double,
or triple dollar signs ($).
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Figure 1.
The Neh6 domain of Nrf2 comprises two conserved regions that include putative β-TrCP
binding sites and a potential PEST sequence.
A) Amino acid sequences corresponding to the Neh6 domain of Nrf2 from mouse (m),
human (h), rat (r), frog (f), and zebrafish (z), along with that of ECH (i.e. chicken Nrf2) have
been aligned using the T-Coffee tool (at http://www.ebi.ac.uk/Tools/msa/tcoffee/). White
letters on a black background represent residues that are identical across at least half of the
species studied, and black letters on a grey background are conserved residues. The two
boxes designated SDS1 and SDS2 contain sequences enriched with Ser and Asp residues.
The solid horizontal bar over residues corresponding to 347 and 385 in mouse Nrf2 depicts a
potential PEST sequence that is enriched with Pro, Glu, Ser and Thr residues (6). Within the
SDS1 and SDS2 boxes, a solid horizonal bar is shown above sequences that represent
putative β-TrCP binding sites. The residues that are predicted to be phosphorylated by
GSK-3, based on the Scansite program (at http://scansite.mit.edu), are shown at the bottom
as vertical arrows.
B) Amino acid sequences of the SDS1 region in the Neh6 domain of mNrf2, hNrf2 and
rNrf2 have been aligned with a similar region in the acidic domain-2 of mNrf1, hNrf1, rNrf1
and TCF11, a splice variant of Nrf1 (the protein shown is the human factor).
C) Amino acid sequences of the SDS2 region in the Neh6 domain of mNrf2, hNrf2 and
rNrf2 have been aligned with a similar region in the Neh6-like domain of mRn1, hNrf1,
rNrf1 and TCF11.
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Figure 2.
Repression of Nrf2 by β-TrCP is abolished by deletion of two separate regions within its
Neh6 domain.
A) Keap1−/− MEFs were transfected for 24 h with pcDNA3.1 expression vectors encoding
V5-tagged mouse Nrf2ΔNeh2 or related mutants that lack SDS1, PEST or the entire Neh6
domain, along with either an empty pcDNA4-FLAG plasmid or a pcDNA4-βTrCP1-FLAG
plasmid. Twenty-four h later, the cells were serum-depleted by transfer to Delbecco’s
modified Eagle’s medium (DMEM) containing 0.5% fetal bovine serum (FBS) for 16 h,
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after which whole cell lysates were prepared and ectopic Nrf2 measured by Western blotting
using mouse anti-V5 antibodies.
B) Keap1−/− MEFs were transfected with the same Nrf2ΔNeh2-V5, Nrf2ΔNeh2,SDS1-V5,
Nrf2ΔNeh2,PEST-V5 and Nrf2ΔNeh2,Neh6-V5 expression vectors used in panel A. Following
transfection, the MEFs were serum-depleted for 16 h before they were treated with CHX for
various periods of time and the relative amounts of ectopic mutant Nrf2 measured by
Western blotting. Results that were significantly higher than the Nrf2ΔNeh2 control with P
values of 0.01-0.001 or <0.001 are indicated with double (**) or triple (***) asterisk signs,
respectively.
C) COS1 cells were co-transfected with an empty pcDNA3.1 expression vector or one
encoding various mutant mouse Nrf2 proteins (as indicated at the bottom of the figure)
along with the murine quinone reductase-based P
-1016/nqo1-Luc reporter construct (2) and
the pRL-TK Renilla control plasmid. At the same time, the cells were also transfected with
combinations of empty vectors and pcDNA4-βTrCP1-FLAG and pCGN/GSK-3βΔ9 as
indicated. Equal amounts of DNA were transfected into COS1 cells in the different
experimental groups. After overnight transfection, the cells were serum-depleted for 16 h,
before ARE-driven luciferase activity was measured. All results were normalized to Renilla
luciferase activity. The data are presented as follows: cells transfected with empty pcDNA4
expression vector in open bars; cells transfected with pcDNA4-FLAG and pcDNA4-
βTrCP1-FLAG in grey bars; cells transfected with pcDNA4-βTrCP1-FLAG and pCGN/
GSK-3βΔ9 solid black bars. Results in which ectopic expression of compound mutant forms
of Nrf2 stimulated an increase in ARE-driven luciferase activity with a P value of 0.05-0.01,
relative to that produced by Nrf2ΔNeh2-V5, are indicated by a single asterisk (*). Results in
which the stimulation of ARE-driven luciferase activity produced by Nrf2 or its mutants was
reduced through forced expression of β-TrCP1 or forced co-expression of β-TrCP and
GSK-3βΔ9 with a P value of 0.05-0.01 or <0.005 are indicated by $ or $$$, respectively.
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Figure 3.
Transcription factor Nrf2 contains two separate sequences in its Neh6 domain to which β-
TrCP can bind.
A) COS1 cells were co-transfected with pcDNA3.1 expression plasmids encoding V5-
tagged mouse Nrf2Δ17-32 or mutants lacking SDS1, SDS2, or SDS1 and SDS2, along with
pcDNA4-βTrCP1-FLAG. Empty pcDNA3.1 vector was included in the transfection mixture
to normalize the amount of DNA to which cells were exposed. Following overnight
transfection, the cells were serum-depleted for 16 h by transfer to DMEM containing 0.5%
FBS before whole cell lysates were prepared. An aliquot (10%) of the lysate was withdrawn
as the input sample, and the remainder was used for the pull-down assay that employed an
antibody against FLAG as described in Materials and Methods.
B) COS1 cells were co-transfected for 24 h with an expression vector for mouse Nrf2Δ17-32-
V5, or its mutants lacking SDSGIS338, SDSEME370 and DSAPGS378, either individually or
as double deletion mutants, along with an expression plasmid for FLAG-tagged β-TrCP1.
As in panel A, β-TrCP1 was pulled-down after the cells had been subjected to 16 h serum-
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depletion using antibodies against FLAG, and the Nrf2 mutants that co-immunoprecipitated
with β-TrCP1 were detected by immunoblotting with antibodies against the V5 epitope.
C) COS1 cells were co-transfected with expression vectors for a YFP-Neh6 fusion protein,
or YFP-Neh6 protein lacking SDSGIS338, SDSEME370 or DSAPGS378, or combinations
thereof, along with an expression plasmid for FLAG-tagged β-TrCP1. The Neh6 domain
mutants that co-immunoprecipitated with β-TrCP1 were detected by immunoblotting with
antibodies against GFP.
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Figure 4.
A peptide sequence in the SDS1 region of the Neh6 domain allows Nrf2 to interact with β-
TrCP in a GSK-3-dependent manner.
A) COS1 cells were co-transfected with expression vectors encoding the Gal4 DNA-binding
domain fused to the Neh6 domain (i.e. Gal4(DBD)-Neh6), or expression vectors for
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Gal4(DBD)-Neh6 containing individual or combined deletion of the SDSGIS338,
SDSEME370 and DSAPGS378 hexapeptides along with an expression vector for the Gal4
activating domain fused to the substrate-binding WD40 domain of β-TrCP1 (Gal4(AD)-
WD40) and the reporter plasmids PTKUAS-Luc and pRL-TK Renilla. Forty-eight h later the
cells were serum-depleted for 16 h by transfer to DMEM containing 0.5% FBS, after which
time Gal4-driven luciferase activity was measured. Significant increases in Gal4-driven
reporter gene activity, relative to that produced by pM-Neh6 alone, with P values of
0.01-0.001 or <0.001 are indicated above the histogram bars by ** or ***, respectively.
Significant decreases in reporter gene activity relative to that produced by Neh6 + WD40
with P values <0.001 are indicated by $$$ on a horizontal line from Neh6 with a vertical line
directed at the relevant data points.
B) COS1 cells were co-transfected with expression vectors for Gal4(DBD)-Neh6,
Gal4(DBD)-Neh6ΔSDSGIS, Gal4(DBD)-Neh6ΔSDSEME or Gal4(DBD)-Neh6ΔDSAPGS and
the expression plasmid for Gal4(AD)-WD40. At the same time, the COS1 cells were
transfected with the reporter plasmids P TKUAS-Luc and pRL-TK Renilla, along with either
an empty expression vector or one encoding GSK-3βΔ9. Following 48 h transfection, the
COS1 cells were serum-depleted for 16 h, during which time a portion was treated with 5
μM CT99021 for 2 h or with 0.1% DMSO vehicle control. The cells were then harvested,
lysed and Gal4-driven luciferase activity measured. Differences in reporter gene activity
produced by a given two-hybrid pair that were observed upon either expression of
GSK-3βΔ9 or treatment with CT99021 with P values of 0.01-0.001 (increase **, or decrease
$$) are indicated by the linked lines above the histogram bars.
C) COS1 cells were transfected with expression vectors as described in panel B, but a
plasmid encoding GSK-3βY216F substituted for that encoding GSK-3βΔ9.
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Figure 5.
The abundance of a Neh6-LacZ fusion protein is controlled by two peptide sequences and
by GSK-3
A) COS1 cells were co-transfected with a pcDNA3.1 expression vector for a V5-tagged
fusion protein comprising Neh6 coupled at its C-terminus to LacZ (i.e. Neh6(LacZ)-V5), or
expression vectors for Neh6(LacZ)-V5 bearing individual or combined deletion of the
SDSGIS338, SDSEME370 and DSAPGS378 hexapeptides from the Neh6 domain along with
an expression plasmid for βTrCP1-FLAG and pRL-TK Renilla as a transfection control. As
further controls, COS1 cells were transfected with the expression plasmid for Neh6(LacZ)-
V5 alone, or were co-transfected with expression plasmids for LacZ-V5 and β-TrCP1-
FLAG; all of these included the Renilla transfection control plasmid. After 24 h transfection,
the cells were serum-depleted for 16 h before β-gal activity was measured and results
normalised against Renilla. Enzyme activity results that are significantly higher than that
produced by Neh6-LacZ with a P value of <0.001 are indicated by ***.
B) COS1 cells were co-transfected with the expression plasmids for Neh6(LacZ)-V5, or its
mutants, and β-TrCP1-FLAG as above along with the expression vector for GSK-3βΔ9.
Thereafter, the cells were transferred to medium containing 0.5% FBS for 16 h, and were
then treated with 5 μM CT99021 or 0.1% DMSO vehicle control for 2 h before being
harvested and β-gal activity measured. The β-galactosidase activity was normalised against
Renilla. The significance of changes in β-gal activity following treatment with CT99021
and/or ectopic expression of GSK-3βΔ9 for an individual Neh6-LacZ fusion protein is
indicated above the histogram bars as outlined in Materials and Methods.
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Figure 6.
β-TrCP-mediated ubiquitylation of Nrf2 involves two separate peptide motifs in the Neh6
domain
A) COS1 cells were co-transfected for 24 h with a pcDNA3.1 expression vector encoding
V5-tagged mouse Nrf2Δ17-32, or mutants lacking SDSGIS338, SDSEME370 or DSAPGS378,
along with expression plasmids for HisUb and β-TrCP1-FLAG. As controls, the cells were
transfected with empty expression vectors, pHisUb alone or pcDNA3.1-Nrf2Δ17-32-V5
without pcDNA4-βTrCP1-FLAG. Following transfection, the cells were serum-depleted for
16 h, after which whole cell lysates were prepared in phosphate-buffered saline. To allow
loading to be assessed, a 10% portion of the lysate was retained as input. The remainder of
each sample was used to purify His-tagged protein separately using Ni2+-agarose beads, and
the total amount of ubiquitylated Nrf2 protein in each sample was determined by Western
blotting with anti-V5 antibodies. The input samples were also immunoblotted with anti-V5
and anti-FLAG antibodies to confirm equal loading of Nrf2 and β-TrCP1.
B) The same ubiquitylation assay was performed for Nrf2Δ17-32-V5, Nrf2Δ17-32,SDSGIS-V5
and Nrf2Δ17-32,DSAPGS-V5 as in panel A, but on this occasion the Nrf2 expression
constructs were co-transfected into COS1 cells with an expression vector for either
GSK-3βΔ9 or an empty vector.
C) The same ubiquitylation assay was performed for Nrf2Δ17-32-V5, Nrf2Δ17-32,SDSGIS-V5
and Nrf2Δ17-32,DSAPGS-V5 as in panel A, but in this case the COS1 cells were treated with 5
μM CT99021 to inhibit GSK-3.
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Figure 7.
β-TrCP binds both phosphorylated and non-phosphorylated Nrf2-derived peptides
containing the DSGIS and DSAPGS sequences.
Biotinylated-peptides, designed around sequences in the SDS1 and SDS2 regions of the
Neh6 domain in mouse Nrf2, were coupled with Streptavidin, which had first been
immobilized on agarose beads, and used in pull-down assays to identify those that were
bound by in vitro translated [35S]methionine-labelled β-TrCP1. A biotinylated ETGE-
containing peptide, representing residues 73-90 of mouse Nrf2, was used as a negative
control.
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A) Ala-scanning substitutions were introduced into the (SGSG)MEFNDSDSGISLNTSPSR
peptide between residues equivalent to Asp-332 and Asn-340 in the Neh6 domain (the
residues changed are shown underlined). Each of the peptides was used in the pull-down
assay, and autoradiography was used to identify β-TrCP1 that bound the peptides. As a
control, lane 1 contained total [35S]methionine-labelled in vitro translated protein. Lane 2
shows [35S]methionine-labelled protein pulled-down by the ETGE peptide. Lane 3 shows
[35S]methionine-labelled protein pulled-down by the wild-type 22-mer peptide, and lanes
4-12 show protein pulled down by the peptides with Ala substitutions across residues
332-340.
B) Ala-scanning substitutions were introduced into the
(SGSG)SEMEELDSAPGSVKQNGP peptide between residues equivalent to Glu-371 and
Ser-374 and Pro-376 and Lys-380 in the Neh6 domain (the residues changed are shown
underlined). As above, lane 1 represents total [35S]methionine-labelled in vitro translated
protein, lane 2 shows protein pulled-down by the ETGE peptide, lane 3 shows protein
pulled-down by the wild-type 22-mer peptide. Lanes 4-7 show [35S]methionine-labelled
protein pulled down by the peptides with Ala substitutions across residues 371-374, and
lanes 8-12 show protein pulled down by peptide with Ala substitutions across residues
376-380.
C) The biotinylated-peptide pull-down assay was used to test whether double
phosphorylation of the peptides increased their binding by β-TrCP; the phosphorylated
residues are indicated in bold italics in the peptide shown above the gel. Lane 1 represents
total [35S]methionine-labelled in vitro translated protein, and lane 2 shows protein pulled
down by the ETGE-containing peptide based on the Neh2 domain. Lanes 3 and 4 show the
protein pulled-down by DSGIS- and DpSGIpS-containing peptides. Lanes 5 and 6 show that
the SDSEME- and pSDpSEME-containing peptides did not pull-down protein. Lanes 7 and
8 show the protein pulled-down by DSAPGS- and DpSAPGpS-containing peptides.
D) The effect of individual phosphorylation of Ser-333, Ser-335, Ser-338 and Ser-342
across the DSGIS-containing peptide on binding by β-TrCP was examined by pull-down
assay. Lane 1 shows total [35S]methionine-labelled in vitro translated protein, and lane 2
shows protein pulled-down by the ETGE-containing peptide based on the Neh2 domain.
Lanes 3 and 9 show protein bound to the non-phosphorylated DSGIS-containing peptide.
Lanes 4-8 show the protein bound to the DSGIS-containing peptide in which only Ser-335 is
phosphorylated, only Ser-338 is phosphorylated, both Ser-335 and Ser-338 are
phosphorylated, Ser-333, Ser-335 and Ser-338 are phosphorylated, and Ser-335, Ser-338
and Ser-342 had been phosphorylated, respectively.
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Figure 8.
Nrf2 is down-regulated by prevention of the inhibitory phosphorylation of GSK-3
A) COS1 cells were transfected with a pcDNA3.1 expression vector for a V5-tagged fusion
protein comprising Neh6(LacZ)-V5 or Neh6(LacZ)-V5 bearing individual deletion of the
SDSGIS338, SDSEME370 and DSAPGS378 from the Neh6 domain for 24 h. Twenty-four h
later the cells were serum depleted by transfer to DMEM containing 0.1% (v/v) FBS for a
further 16 h before the cells were treated with either 10 μM LY294002, 5 μM MK-2206 or
with vehicle (0.1% (v/v) DMSO) in media containing 0.1% (w/v) FBS for 8 h. Whole-cell
lysates were harvested and proteins were resolved in SDS-PAGE and gels were immuno-
blotted with the indicated antibodies. The antibody that recognised phospho-GSK-3β (Ser-9)
was from Abcam (ab30619). Gapdh was used as an internal control.
B) Keap1−/− MEFs were seeded in 60 mm petri-dishes in DMEM containing 10% FBS 24 h
prior to serum depletion (0.1% FBS) for a further 16 h. Thereafter, the cells were treated for
8 h with 1.0, 2.5, 10 or 40 μM LY294002 or 0.25, 1.0, 5.0 or 10 μM MK-2206, all of which
were dissolved in DMSO to a final concentration of 0.1% (by vol), in media containing
0.1% (w/v) FBS; 0.1% (v/v) DMSO was used as vehicle control. Whole-cell lysates were
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harvested and proteins were resolved in SDS-PAGE and gels were immunoblotted with the
indicated antibodies. Gapdh was used as a sample loading control.
C) Keap1−/− MEFs were grown in 60 mm petri-dishes in DMEM containing 10% FBS 24 h
prior to serum depletion (0.1% FBS) for 16 h, as described in panel B above. The fibroblasts
were then treated with LY294002 or MK-2206 in medium containing 0.1% FBS, at the
doses indicated, for 2 h before they were transferred to fresh medium containing 0.1% FBS
for 6 h. Thereafter, the fibroblasts were harvested, total RNA extracted, and mRNA for
Nqo1, Hmox1, Gclc, Gclm, Gsta1 and Gstm1 measured by TaqMan chemistry as described
by Higgins et al (61). The solid horizontal bar indicates that mRNA levels in MEFs treated
with kinase inhibitors in medium containing 0.1% FBS were compared with MEFs treated
with DMSO vehicle control in medium containing 0.1% FBS.
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Figure 9.
The sensitivity of Keap1−/− MEFs to anti-cancer drugs is increased by prevention of
inhibitory phosphorylation of GSK-3
Keap1-null MEFs (1.32 × 104) were seeded in 96-well microtitre plates 24 h prior to serum
depletion (0.1% FBS) for a further 16 h. The cells were then pre-treated for 8 h with (A) 10
μM LY29400 2 or 10 μM LY294002 plus 5 μM CT99021 (B) 5 μM MK-2206 or 5 μM
MK-2206 plus 5 μM CT99021 in media containing 0.1% (w/v) FBS; in both (A) and (B) the
kinase inhibitors were dissolved in DMSO to a final concentration of 0.1% (by volume).
Thereafter, the MEFs were challenged for 48 h with increasing doses of acrolein (dissolved
in ethanol), cisplatin (dissolved in media), chlorambucil (dissolved in DMSO) or a constant
amount of vehicle control in media containing 0.1% (w/v) FBS. Finally, MTT was added to
each of the wells and cell viability assessed by reduction of the dye (OD570), as described in
the Materials and Methods section. The relative viability of Keap1−/− MEFs following
exposure to different concentrations of acrolein, cisplatin or chlorambucil is shown as mean
values ± SEM from three separate experiments. The EC50 dose represents the effective
concentration of acrolein, cisplatin or chlorambucil required to reduce the viability of
Keap1-null MEFs to 50% of maximum; the EC50 results shown in the table are mean values,
with standard deviation as the 95% confidence interval presented in parenthesis. The
statistical significance of differences in EC50 of Keap1-null MEFs for acrolein, cisplatin or
chlorambucil with or without pre-treatment with LY294002 and/or CT99021, or MK-2206
and/or CT99021 were calculated by Two-Way ANOVA followed by Bonferroni post-tests.
C) The MTT curve for Keap1-null MEFs treated for 48 h with different doses of LY294002
or MK-2206 in medium containing 0.1% FBS is shown as a control.
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Figure 10.
Down-regulation of Nrf2 in human lung A549 cells decreases expression of cytoprotective
genes
A) A549 cells were seeded and grown in DMEM that contained 10% FBS for about 24 h
before transfer to DMEM containing 0.1% FBS for 16 h. The cells were then treated for 8 h
with various doses of either LY294002 or MK-2206 in DMEM containing 0.1% FBS, as
indicated, before lysates were prepared and the levels of individual proteins measured by
Western blotting. The antibody that recognised both phospho-GSK-3α (Ser-21) and
phospho-GSK-3β (Ser-9) was from Cell Signalling (#9331).
B) A549 cells were grown as described above. After serum depletion for 16 h, they were
treated for 2 h with various doses of LY294002 or MK-2206 and transferred to fresh DMEM
containing 0.1% FBS for a further 6 h before being harvested. Messenger RNA levels were
measured by TaqMan RT-PCR.
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Figure 11.
The sensitivity of A549 cells to chemotherapeutic agents is increased by inhibition of the
PI3K-PKB/Akt pathway
A549 cells were seeded and grown in 96-well plates for 24 h before being subjected to
serum depletion (in 0.1% FBS) for 16 h.
A) The A549 cells were then pretreated for 8 h with LY294002, or LY294002 plus
CT99021, before they were challenged with various doses of acrolein, cisplatin or
chlorambucil for 48 h and cytotoxicity measured using the MTT assay.
B) The A549 cells were pretreated with MK-2206, or MK-2206 plus CT99021, for 8 h
before being exposed to acrolein, cisplatin or chlorambucil for 48 h and MTT cytotoxicity
testing performed.
C) An MTT curve for A549 cells treated for 48 h with different doses of LY294002,
MK-2206 or CT99021 in medium containing 0.1% FBS is shown as a control.
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Figure 12.
Repression of Nrf2 by β-TrCP occurs in both a GSK-3-dependent and a GSK-3-independent
manner
Nrf2 is subject to dual regulation by Keap1 and β-TrCP. The cartoon shows that Nrf2 is
repressed by Keap1 though DLG and ETGE motifs in its Neh2 domain, both of which are
required for ubiquitylation of the CNC-bZIP protein by Cul3-Rbx1. By contrast, Nrf2 is
repressed by β-TrCP though DSGIS and DSAPGS motifs in its Neh6 domain, each of which
is sufficient for ubiquitylation of the CNC-bZIP protein by Cul1-Rbx1. Phosphorylation of
the DSGIS motif increases its degron activity, and this is positively regulated by GSK-3.
The GSK-3 inhibitor CT99021 decreases the degron activity of the DSGIS destruction motif
whereas PI3K and PKB/Akt inhibitors increase the degron activity of the DSGIS motif. By
contrast, the DSAPGS destruction motif is not influenced by GSK-3 activity.
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